Regulated information

Get easy access to all the information you need. The documentation center allows you to open, send by e-mail or download any document. Feel free to use the filters and add several documents to your basket.

102 publications

Name	Date	Type
[VIDEO ]Présentation des résultats 2020 - french Présentation analystes & investisseurs - 1er avril 2021	01/04/2021	Annual Report
[VIDEO] Présentation des résultats semestriels 2021 - french Présentation analystes & investisseurs - 29 juillet 2021	29/07/2021	Half Year Report
[Video] Présentation des résultats semestriels 2022 - french Présentation analystes & investisseurs - 15 septembre 2022	29/07/2021	Half Year Report
2011 ACTIVITY REPORT Our business: animals. Our advantage: people.	12/04/2012	Annual Report
2011 annual earnings Lure (France), April 03, 2012 – The Vétoquinol Board Meeting of March 26, 2012 has reviewed the Group’s business and approved the 2011 financial statements.	03/04/2012	Public releases
2011 ANNUAL RESULTS SFAF meeting April 4, 2012	05/04/2012	Annual Report
2011, a year of transition Lure (France), January 24, 2012 – In 2011, Vétoquinol achieved sales of €284.1 million, 0.7% up on the previous year and stable on a like-for-like basis.	24/01/2012	Public releases
2013 calendar of financial communication December 20, 2012 (Lure, France) – Vétoquinol published its calendar of financial communication for 2013.	20/12/2012	Agenda
2020 annual results 2020 sales: €427.5m (up 8.0% as reported) EBIT before depreciation of assets arising from acquisitions: €65.3m (up 33.5%) Net income - Group share: €19.2m (4.5% of sales) Cash flow: €92.2m	01/04/2021	Public releases
2020 sales: €427.5M (up 8.0% as reported, up 10.9% at constant exchange rate) essentials sales: €220.6M (up 15.7% as reported, up 17.3% at constant exchange rate) Vetoquinol CEO Matthieu Frechin said: “2020 was an exceptional year on a number of counts. Above all, it is important to pay tribute to our teams, whose hard work and exemplary dedication allowed us to manage the impact of the health crisis. Year on year, we achieved double-digit sales growth at constant exchange rates, driven by our Essentials products. This momentum accounts for additional sales of €43 million (at constant exchange rates). We also completed a major acquisition in the form of the Drontal® and Profender® product ranges, entailing three structural effects for Vetoquinol: a scale effect, a product mix effect in the Essentials range and potential extensions, the first of which has been confirmed in January 2021 for the Australian market. We are optimistic for our business outlook in 2021, while being vigilant in relation to the global sanitary situation.”	21/01/2021	Public releases